WO2016008084A1 - Autologous lactic acid bacteria manufacturing method and system - Google Patents
Autologous lactic acid bacteria manufacturing method and system Download PDFInfo
- Publication number
- WO2016008084A1 WO2016008084A1 PCT/CN2014/082208 CN2014082208W WO2016008084A1 WO 2016008084 A1 WO2016008084 A1 WO 2016008084A1 CN 2014082208 W CN2014082208 W CN 2014082208W WO 2016008084 A1 WO2016008084 A1 WO 2016008084A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- acid bacteria
- producing
- individual
- autologous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
An autologous lactic acid bacteria manufacturing method and system, utilizing an individual or a sample of a relative thereof comprising lactic acid bacteria to screen out lactic acid bacteria suitable for the individual; by supplementation with a modified lactic acid bacteria product made autologously or from the relative, the individual can recover an original intestinal microbiota thereof, thereby accurately supplementing lactic acid bacteria of a human body.
Description
自体来源乳酸菌的制造方法及系统 Method and system for producing self-derived lactic acid bacteria
技术领域 Technical field
本发明涉及一种乳酸菌的制造方法， 特别是自体来源乳酸菌的制造方法。 本 发明还涉及一种生产自体乳酸菌的系统。 背景技术 The present invention relates to a method for producing a lactic acid bacterium, and more particularly to a method for producing a lactic acid bacterium of an autologous source. The invention also relates to a system for producing autologous lactic acid bacteria. Background technique
我们每天所面对的环境及吃的食物中， 几乎都含有各式各样的微生物， 但人 们通过长期的经验以各种烹煮食物的方法， 除了使食物美味可口外， 更可消灭或 减少微生物， 让人们吃的更安全。 然而， 并非所有的微生物都是有害的， 对人有 益的微生物也相当多而其对人有益的方式， 可以分成提供微生物的代谢物或发酵 产物， 如抗生素、 味精、 酒、 酱油、 醋等， 及另一种方式是食用微生物本身， 例 如乳酸菌、 香菇、 灵芝、 冬虫夏草、 酵母菌等， 其中， 乳酸菌和部分酵母菌则常 以活的微生物状态进入人体， 而以活的微生物状态进入人体的方式， 对人体健康 是较有正面效益的。 Almost every day we face the environment and the food we eat, we have a wide variety of microorganisms, but through long-term experience, we can eliminate or reduce the food in addition to making the food delicious. Microorganisms make people eat safer. However, not all microorganisms are harmful, and human beneficial microorganisms are also quite beneficial and beneficial to humans. They can be divided into metabolites or fermentation products that provide microorganisms, such as antibiotics, monosodium glutamate, wine, soy sauce, vinegar, etc. And another way is to consume the microorganism itself, such as lactic acid bacteria, shiitake mushroom, ganoderma lucidum, cordyceps sinensis, yeast, etc., wherein lactic acid bacteria and some yeasts often enter the human body in a living microbial state, and enter the human body in a living microbial state. It is more positive for human health.
因此， 人体内会包含许多微生物， 而微生物中又可分成对人体有益的益生菌 及对人体有害的有害菌； 而， 目前益生菌的定义为 "活的微生物， 可改善宿主 (如 动物或人类)肠内微生物相的平衡， 并对宿主有正面的效益"； 而益生菌主要所指的 即是乳酸菌和部分酵母菌， 其中又以 "乳酸菌"为最重要的一群。 乳酸菌对宿主 有正面的效益， 主要在于宿主发挥整肠效果， 乳酸菌可能是通过以下四种作用机 制而发挥整肠效果： 一、 乳酸菌产生有机酸以降低肠道的酸碱值， 而使肠道内的 环境适合乳酸菌生存而非有害菌； 二、 该乳酸菌可与有害菌竞争养份， 使有害菌 不易取得养分； 三、 该乳酸菌附着于肠黏膜， 以减少有害菌的繁殖场所； 四、 借 助该乳酸菌产生抗菌物质， 使肠道内的有害菌减少等。 乳酸菌对于宿主除了具有 整肠效果之外， 更有免疫调节作用， 通过乳酸菌剌激活化免疫系统， 且不同的乳 酸菌菌种会引起不同的免疫反应， 并增强非特异性的先天免疫力， 还能适当调节 免疫反应达到平衡状态， 因而改善过敏现象。 乳酸菌对宿主还具有改善代谢作用， 以下说明叙述以人体为例， 乳酸菌可在人体的结肠中针对不能消化的食物残余物 进行发酵作用， 而降低结肠癌的发生率。 Therefore, the human body contains many microorganisms, and the microorganisms can be divided into probiotics beneficial to the human body and harmful bacteria harmful to the human body; however, probiotics are currently defined as "living microorganisms, which can improve the host (such as animals or humans). The balance of the microbial phase in the intestine has positive effects on the host"; while the probiotics mainly refer to lactic acid bacteria and some yeasts, among which "lactic acid bacteria" are the most important group. Lactic acid bacteria have positive effects on the host, mainly because the host exerts the effect of the whole intestine. The lactic acid bacteria may exert the effect of the whole intestine through the following four mechanisms of action: 1. The lactic acid bacteria produce organic acid to lower the pH value of the intestine, and make the intestinal tract The environment is suitable for lactic acid bacteria to survive rather than harmful bacteria; Second, the lactic acid bacteria can compete with harmful bacteria to make nutrients, so that harmful bacteria are not easy to obtain nutrients; Third, the lactic acid bacteria adhere to the intestinal mucosa to reduce the breeding sites of harmful bacteria; Lactic acid bacteria produce antibacterial substances, which reduce harmful bacteria in the intestines. In addition to the intestinal effect, the lactic acid bacteria have an immunomodulatory effect, activate the immune system through lactic acid bacteria, and different lactic acid bacteria can cause different immune responses and enhance non-specific innate immunity. Regulates the immune response to an equilibrium state, thus improving allergy. The lactic acid bacteria also have an improved metabolic effect on the host. The following description describes the human body as an example. The lactic acid bacteria can ferment the indigestible food residue in the colon of the human body, thereby reducing the incidence of colon cancer.
由于， 人体内的益生菌与有害菌彼此是竞争消长的动态平衡关系， 例如当人 体健康时通常是益生菌多于有害菌， 或益生菌较有害菌更占优势； 但当人体不适、
饮食、 环境改变、 压力或老化等因素， 会打破益生菌多于有害菌， 或益生菌较有 害菌更占优势的平衡状态， 而使益生菌减少或居于劣势。 幸而， 乳酸菌可由外部 补充含乳酸菌产品以增加人体肠道的益生菌， 进而维持正常肠道的菌相； 该乳酸 菌产品包括优格或酸奶等。 Because the probiotics and harmful bacteria in the human body are in a dynamic equilibrium relationship with each other, for example, when the human body is healthy, the probiotics are more than the harmful bacteria, or the probiotics are more dominant than the harmful bacteria; Factors such as diet, environmental change, stress or aging can break the probiotics more than harmful bacteria, or the probiotics are more dominant than the harmful bacteria, and the probiotics are reduced or at a disadvantage. Fortunately, the lactic acid bacteria can be externally supplemented with a lactic acid bacteria product to increase the probiotic bacteria in the human intestinal tract, thereby maintaining the bacterial phase of the normal intestinal tract; the lactic acid bacteria product includes yoghurt or yogurt.
但是， 虽然当人体内的益生菌减少时， 可通过一般市面上所贩卖的乳酸菌产 品的乳酸菌 (以下称为市售乳酸菌)补充，但市售乳酸菌能否通过胃部的酸性环境及 肠道的碱性环境， 都是影响乳酸菌是否能达到整肠功效的影响因子。 此外， 即使 市售乳酸菌具有耐酸耐碱的特性， 但每个人的体内环境都相当复杂且都不完全相 同， 即， 人与人之间都存在有个体差异， 因此， 市售乳酸菌不可能适合生存于每 个人的体内， 或者， 即使能生存但对每个人体并非都能产生正面效益， 即市售乳 酸菌的正面效益是因人而异的。 此外， 市售乳酸菌即使能生存于某个个体， 且使 该个体的肠道菌相达到一定平衡状态， 但由于市售乳酸菌并非来自于该个体本身， 因此， 与该个体本身原本的肠道菌相仍有差异。 However, when the probiotics in the human body are reduced, it can be supplemented by lactic acid bacteria (hereinafter referred to as commercially available lactic acid bacteria) which are generally sold on the market, but whether the commercially available lactic acid bacteria can pass through the acidic environment of the stomach and the intestinal tract. Alkaline environment is an influencing factor that affects whether lactic acid bacteria can achieve the function of the whole intestine. In addition, even if the commercially available lactic acid bacteria have the characteristics of acid and alkali resistance, the internal environment of each person is quite complicated and not identical, that is, there are individual differences between people, and therefore, commercially available lactic acid bacteria cannot be suitable for survival. In everyone's body, or even if it can survive, it does not produce positive benefits for everyone. The positive benefits of commercially available lactic acid bacteria vary from person to person. In addition, even if the commercially available lactic acid bacteria can survive in an individual and the intestinal flora of the individual reaches a certain equilibrium state, since the commercially available lactic acid bacteria are not derived from the individual itself, the original intestinal bacteria of the individual itself There are still differences.
再者， 现在的过敏人口日益增多， 但若通过补充市售乳酸菌而非来自于该个 体本身的乳酸菌， 来改善过敏情况， 并不见得真的有助于改善过敏现象， 因为乳 酸菌之所以能够改善过敏现象， 是通过乳酸菌剌激活化免疫系统， 且不同的乳酸 菌菌种会引起不同的免疫反应， 并还能适当调节免疫反应达到平衡状态， 但由于 人与人之间都存在有个体差异， 因此市售乳酸菌所引发的免疫反应的程度也不同， 因此有可能会引起相当严重程度的免疫反应， 反而使得过敏现象加重。 Furthermore, the current allergic population is increasing, but if you supplement the commercially available lactic acid bacteria instead of the lactic acid bacteria from the individual itself to improve allergies, it does not really help to improve allergies, because lactic acid bacteria can improve Allergic phenomenon is the activation of the immune system through lactic acid bacteria, and different lactic acid bacteria species can cause different immune reactions, and can also properly regulate the immune response to reach equilibrium, but because there are individual differences between people, The degree of immune response elicited by commercially available lactic acid bacteria is also different, so it is likely to cause a relatively serious degree of immune response, which in turn makes the allergic phenomenon worse.
综上所述， 为了改善当人体补充市售乳酸菌时， 对于人体可能会产生的影响 及疑虑； 因此， 本发明人认为， 当人体因不适而使体内乳酸菌减少或居于劣势时， 应补充来自于自体本身或亲属的乳酸菌， 藉以增加乳酸菌存活肠道的机率， 且恢 复人体自身原本健康正常肠道的菌相。 而且， 由于是补充自体本身或亲属的乳酸 菌， 更可以降低人体内对自体本身或亲属乳酸菌所产生的免疫反应， 基于此以解 决当人体补充市售乳酸菌时， 对于乳酸菌在人体内是否会产生正面效益的疑虑， 且能更确实地达到人体补充乳酸菌的目的。 发明内容 In summary, in order to improve the impact and doubts that may occur on the human body when the human body supplements the commercially available lactic acid bacteria; therefore, the inventors believe that when the human body is reduced or at a disadvantage due to discomfort, the body should be supplemented by The lactic acid bacteria of the body itself or relatives can increase the chance of the lactic acid bacteria surviving the intestines, and restore the original phase of the human body's original healthy and normal intestinal tract. Moreover, since it is a lactic acid bacteria supplemented by the body itself or a relative, it can reduce the immune response to the body itself or the relative lactic acid bacteria, thereby solving the problem that whether the lactic acid bacteria will be positive in the human body when the human body supplements the commercially available lactic acid bacteria. The doubts about the benefits, and can more reliably achieve the purpose of the body to supplement lactic acid bacteria. Summary of the invention
本发明是一种自体来源乳酸菌的制造方法， 包括下列步骤： The invention relates to a method for manufacturing lactic acid bacteria of autologous origin, comprising the following steps:
(a)从一个体采集该个体的含有乳酸菌的样本；
(b)从该个体的含有乳酸菌的样本中筛选乳酸菌菌种， 并将筛选出的乳酸菌菌种进 行纯化培养； (a) collecting a sample of the individual containing lactic acid bacteria from a body; (b) screening the lactic acid bacteria species from the individual lactic acid bacteria-containing sample, and purifying and cultivating the selected lactic acid bacteria species;
(C)对从该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种分别进行菌种鉴定及生 理测试； (C) performing strain identification and physiological testing on the lactic acid bacteria strains selected from the lactic acid bacteria-containing samples for screening and purification;
(d)依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种鉴定结果， 用 以比对安全可靠 (Generally Regarded as Safe, GRAS)等级的 FDA认可安全表 列， 从而判断从该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种是否为安全可 靠等级的乳酸菌菌种； 以及 (d) screening and purifying the cultured lactic acid bacteria species according to the lactic acid bacteria-containing sample in the step (c), for comparing the FDA-approved safety list of the Generally Regarded as Safe (GRAS) grade, thereby judging from The lactic acid bacteria-containing sample is used to screen and purify whether the cultured lactic acid bacteria species are safe and reliable grades of lactic acid bacteria;
(e)另依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种生理测试结 果， 以决定将步骤 (d)中该安全可靠等级乳酸菌菌种， 制成乳酸菌产品。 (e) Further screening and purifying the physiological test results of the cultured lactic acid bacteria according to the sample containing the lactic acid bacteria in the step (c), and determining the safe and reliable grade of the lactic acid bacteria in the step (d) to prepare the lactic acid bacteria product.
通过本发明的制造方法， 该个体可以获得来自自身或其亲属的乳酸菌， 因此， 当该个体因不适、 饮食、 环境改变、 压力或老化等因素， 而使得益生菌少于有害 菌， 或益生菌较有害菌居于劣势时， 该个体可通过补充由自体或其亲属来源所制 成的该乳酸菌产品， 由于所补充的乳酸菌是来自于个体本身或其亲属， 因此可较 市售乳酸菌更增加乳酸菌存活于肠道的机率， 且可恢复该个体自身原本健康正常 肠道的菌相， 且由于是补充该个体自体本身或其亲属的乳酸菌， 更可以降低个体 体内对自体乳酸菌所产生的免疫反应， 从而解决当该个体补充市售乳酸菌时， 对 于市售乳酸菌在人体内是否会产生正面效益的疑虑， 且能更确实地达到人体补充 乳酸菌的目的。 By the manufacturing method of the present invention, the individual can obtain lactic acid bacteria from himself or his relatives, and therefore, the probiotics are less than harmful bacteria, or probiotics, due to factors such as discomfort, diet, environmental changes, stress or aging. When the more harmful bacteria are at a disadvantage, the individual can supplement the lactic acid bacteria product produced by the source of the autologous or its relatives. Since the supplemented lactic acid bacteria are from the individual or its relatives, the lactic acid bacteria can be more than the commercially available lactic acid bacteria. In the intestinal tract, and can recover the original healthy and normal intestinal tract of the individual, and because it supplements the lactic acid bacteria of the individual itself or its relatives, it can reduce the immune response to the autologous lactic acid bacteria in the individual, thereby When the individual supplements the commercially available lactic acid bacteria, it is doubtful whether the commercially available lactic acid bacteria will produce positive benefits in the human body, and can more reliably achieve the purpose of supplementing the human body with lactic acid bacteria.
依据本发明的自体来源乳酸菌的制造方法， 在较佳实施例中， 该生理测试是 选自革兰氏染色、 抗生素耐受性、 抗菌活性、 耐酸试验、 耐胆盐试验、 耐盐试验 组合中的一种或两种以上的组合。 According to the method for producing an autologously derived lactic acid bacterium according to the present invention, in a preferred embodiment, the physiological test is selected from the group consisting of Gram staining, antibiotic resistance, antibacterial activity, acid resistance test, bile salt resistance test, and salt tolerance test combination. One or a combination of two or more.
依据本发明的自体来源乳酸菌的制造方法， 在较佳实施例中， 采集该个体的 含有乳酸菌的样本的采集器是一可降低含氧量的样本采集器。 According to the method of producing an autologously derived lactic acid bacterium according to the present invention, in a preferred embodiment, the collector for collecting the lactic acid bacteria-containing sample of the individual is a sample collector capable of reducing the oxygen content.
依据本发明的自体来源乳酸菌的制造方法， 在另一较佳实施例中， 将安全可 靠等级的乳酸菌菌种冷冻干燥形成一菌粉， 再以该菌粉制成乳酸菌产品供该个体 或其亲属使用， 而该乳酸菌产品包含粉包、 饮品、 果冻、 优格、 乳酸菌颗粒或胶 本发明另提供一种生产自体乳酸菌的系统， 其包含： 一乳酸菌储存装置， 用 于储存从一个体的含有乳酸菌的样本所搜集的乳酸菌； 一分析乳酸菌装置， 用于
分析并储存自该个体的含有乳酸菌的样本所搜集的该乳酸菌的资料； 与一乳酸菌 生产装置， 其连接至该乳酸菌储存装置与该分析乳酸菌装置， 用于将该分析乳酸 菌装置所分析适合该个体的乳酸菌从该乳酸菌储存装置取出并制成一乳酸菌产According to the method for producing a self-derived lactic acid bacterium according to the present invention, in another preferred embodiment, a lactic acid bacteria strain of a safe and reliable grade is freeze-dried to form a bacterium powder, and the lactic acid bacteria product is prepared from the bacterium powder for the individual or a relative thereof. The lactic acid bacteria product comprises a powder packet, a drink, a jelly, a yogurt, a lactic acid bacteria particle or a glue. The invention further provides a system for producing an autologous lactic acid bacteria, comprising: a lactic acid bacteria storage device for storing lactic acid bacteria from a body a sample of lactic acid bacteria collected; an analytical lactic acid bacteria device, used for Analyzing and storing data of the lactic acid bacteria collected from the lactic acid bacteria-containing sample of the individual; and a lactic acid bacteria production device connected to the lactic acid bacteria storage device and the analytical lactic acid bacteria device for analyzing the analyzed lactic acid bacteria device for the individual Lactic acid bacteria are taken out from the lactic acid bacteria storage device and made into a lactic acid bacteria
PP
ΡΠ o ΡΠ o
依据本发明的生产自体乳酸菌的系统， 在较佳实施例中， 该乳酸菌的数据是 选自由革兰氏染色、 耐酸测试、 耐胆盐测试、 耐盐性分析、 抗生素耐受性分析与 抗菌活性分析所组成的群组。 According to the system for producing autologous lactic acid bacteria according to the present invention, in a preferred embodiment, the data of the lactic acid bacteria are selected from the group consisting of Gram staining, acid resistance test, bile salt resistance test, salt tolerance analysis, antibiotic resistance analysis and antibacterial activity. Analyze the group consisting of.
依据本发明的生产自体乳酸菌的系统， 在较佳实施例中， 该乳酸菌产品包含 粉包、 饮品、 果冻、 优格、 乳酸菌颗粒或胶囊。 According to the system for producing an autologous lactic acid bacteria according to the present invention, in a preferred embodiment, the lactic acid bacteria product comprises a powder packet, a drink, a jelly, a yogurt, a lactic acid bacteria granule or a capsule.
本发明的生产自体乳酸菌的系统， 其设置于一乳酸菌生产公司， 另包含一管 理装置， 该管理装置连接至该乳酸菌生产装置， 其中该管理装置储存有该个体所 签署的合约， 并依照该合约管理该乳酸菌生产装置。 The system for producing an autologous lactic acid bacteria of the present invention, which is provided in a lactic acid bacteria production company, further comprising a management device connected to the lactic acid bacteria production device, wherein the management device stores a contract signed by the individual, and according to the contract The lactic acid bacteria production device is managed.
依据本发明的生产自体乳酸菌的系统， 在较佳实施例中， 该合约约定该个体 同意该乳酸菌生产公司无偿使用该乳酸菌于该乳酸菌生产公司自制产品； 在另一 较佳实施例中， 该合约约定该个体同意该乳酸菌生产公司将该乳酸菌转卖第三方 且该乳酸菌生产公司须提成该乳酸菌售价的一定比例予该个体。 附图说明 According to the system for producing an autologous lactic acid bacteria according to the present invention, in a preferred embodiment, the contract stipulates that the individual agrees that the lactic acid bacteria producing company uses the lactic acid bacteria for the self-made product of the lactic acid bacteria producing company; in another preferred embodiment, the contract It is agreed that the individual agrees that the lactic acid bacteria production company resells the lactic acid bacteria to a third party and that the lactic acid bacteria production company must present a certain percentage of the lactic acid bacteria price to the individual. DRAWINGS
图 1是本发明的方法的流程图。 Figure 1 is a flow chart of the method of the present invention.
图 2 是本发明的生产自体乳酸菌的系统的方块示意图。 具体实施方式 Figure 2 is a block diagram showing the system for producing autologous lactic acid bacteria of the present invention. detailed description
以下通过附图说明本发明的构造、 特点与实施例， 以使得本领域技术人员对 于本发明有更进一步的了解。 The construction, features and embodiments of the present invention will be described in the following description of the present invention in order to provide a further understanding of the invention.
请参阅图 1， 本发明是一种自体来源乳酸菌的制造方法， 包括下列步骤： Please refer to FIG. 1. The present invention relates to a method for producing a self-derived lactic acid bacterium, comprising the following steps:
(a)从一个体采集该个体的含有乳酸菌的样本； (a) collecting a sample of the individual containing lactic acid bacteria from a body;
(b)从该个体的含有乳酸菌的样本中筛选乳酸菌菌种， 并将筛选出的乳酸菌菌种进 行纯化培养； (b) screening the lactic acid bacteria species from the individual lactic acid bacteria-containing sample, and purifying the selected lactic acid bacteria species;
(c)对从该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种分别进行菌种鉴定及生 理测试， 该生理测试选自革兰氏染色、 抗生素耐受性、 抗菌活性、 耐酸试验、 耐
胆盐试验、 耐盐试验组合中的一种或两种以上的组合； (c) performing strain identification and physiological tests on the lactic acid bacteria strains selected from the lactic acid bacteria-containing samples, which are selected from the group consisting of Gram stain, antibiotic resistance, antibacterial activity, acid resistance test, and resistance test. One or a combination of two or more of a combination of a bile salt test and a salt tolerance test;
(d)依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种鉴定结果， 用 以比对安全可靠 (Generally Regarded as Safe, GRAS)等级的 FDA认可安全表 列， 从而判断从该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种是否为安全可 靠等级的乳酸菌菌种； 以及 (d) screening and purifying the cultured lactic acid bacteria species according to the lactic acid bacteria-containing sample in the step (c), for comparing the FDA-approved safety list of the Generally Regarded as Safe (GRAS) grade, thereby judging from The lactic acid bacteria-containing sample is used to screen and purify whether the cultured lactic acid bacteria species are safe and reliable grades of lactic acid bacteria;
(e)另依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种生理测试结 果， 以决定将步骤 (d)中该安全可靠等级乳酸菌菌种， 制成乳酸菌产品供该个体或 其亲属使用。 (e) further screening and purifying the physiological test results of the cultured lactic acid bacteria strain according to the sample containing the lactic acid bacteria in the step (c), to determine the safe and reliable grade of the lactic acid bacteria strain in the step (d), and preparing the lactic acid bacteria product for the individual Or use by their relatives.
通过本发明的制造方法， 该个体可以获得来自自体或其亲属的乳酸菌， 因此， 当该个体因不适、 饮食、 环境改变、 压力或老化等因素， 而使得益生菌少于有害 菌， 或益生菌较有害菌居于劣势时， 该个体可通过补充由自体或其亲属来源所制 成的该乳酸菌产品， 由于所补充的乳酸菌是来自于该个体本身或其亲属， 因此可 较市售乳酸菌更增加乳酸菌存活于肠道的机率， 且可恢复该个体自身原本健康正 常肠道的菌相， 且由于是补充该个体自体本身或其亲属的乳酸菌， 更可以降低该 个体体内对自体乳酸菌所产生的免疫反应， 从而解决当该个体补充市售乳酸菌时， 对于市售乳酸菌在人体内是否会产生正面效益的疑虑， 且能更确实地达到人体补 充乳酸菌的目的。 By the manufacturing method of the present invention, the individual can obtain lactic acid bacteria from the autologous or relatives thereof, and therefore, the probiotic is less than harmful bacteria, or probiotics, due to factors such as discomfort, diet, environmental change, stress or aging. When the more harmful bacteria is at a disadvantage, the individual can supplement the lactic acid bacteria product prepared from the source of the autologous or its relatives. Since the supplemented lactic acid bacteria are derived from the individual or its relatives, the lactic acid bacteria can be increased more than the commercially available lactic acid bacteria. Survival in the intestine, and restore the original healthy and normal intestinal flora of the individual, and because it supplements the lactic acid bacteria of the individual itself or its relatives, it can reduce the immune response to the autologous lactic acid bacteria in the individual. Therefore, when the individual supplements the commercially available lactic acid bacteria, it is doubtful whether the commercially available lactic acid bacteria have a positive effect in the human body, and can more reliably achieve the purpose of supplementing the human body with lactic acid bacteria.
通过本发明制造方法所获得的自体来源乳酸菌， 储存于一乳酸菌生产公司， 该个体与该乳酸菌生产公司以合约约定所获得的乳酸菌的使用， 例如该合约约定 该个体同意该乳酸菌生产公司无偿使用该乳酸菌于该乳酸菌生产公司自制产品， 而该乳酸菌生产公司需提供该个体菌株筛选报告， 使该个体透过长期菌株筛选报 告， 了解自身好菌比例。 该乳酸菌生产公司也通过创建自体乳酸菌云端数据库， 使该个体可随时通过系统提出服务需求。 又例如， 该合约约定该个体同意该乳酸 菌生产公司将该乳酸菌转卖给第三方且该乳酸菌生产公司须提成该乳酸菌售价的 一定比例予该个体。 The lactic acid bacterium obtained by the manufacturing method of the present invention is stored in a lactic acid bacteria production company, and the lactic acid bacteria obtained by the individual and the lactic acid bacteria production company are contractually agreed, for example, the contract stipulates that the individual agrees that the lactic acid bacteria production company uses the lactic acid bacteria free of charge. The lactic acid bacteria are self-made products of the lactic acid bacteria production company, and the lactic acid bacteria production company needs to provide a screening report of the individual strain, so that the individual can understand the proportion of good bacteria through the long-term strain screening report. The lactic acid bacteria production company also creates an autologous lactic acid bacteria cloud database, so that the individual can request service through the system at any time. For another example, the contract stipulates that the individual agrees that the lactic acid bacteria production company resells the lactic acid bacteria to a third party and that the lactic acid bacteria production company must present a certain percentage of the lactic acid bacteria price to the individual.
另外， 由于乳酸菌多为厌氧菌， 为了使该含有乳酸菌的样本中的乳酸菌的存 活率增加， 进而使步骤 (b)的筛菌步骤能够得到更多更完整的乳酸菌菌种， 因此， 采集该个体含有乳酸菌的样本的采集器是一可降低含氧量的样本采集器， 且采集 过程中， 该含有乳酸菌的样本以于室温下放置不超过 30分钟的新鲜含有乳酸菌的 样本为佳， 尤其以出生未满一年的胎儿含有乳酸菌的粪便为佳， 因为肠道内微生
物种类会随着年龄的增加而减少； 将含有乳酸菌的样本置于可密封的采集器， 以 使该含有乳酸菌的样本可与外部隔绝， 且于该采集器内置脱氧剂及氧气指示剂， 以使该采集器内部呈低含氧状态， 且为避免采集器可能于送筛检过程中有不易察 觉的破损而使得内部呈高含氧状态 (为一般大气中的含氧量)，或者脱氧剂已经反应 完全而无法继续脱氧时， 因此该采集器呈高含氧状态， 但由于含氧量的多寡是用 无法用肉眼判定的， 因此通过该氧气指示剂以使该采集器的使用者能够轻易判断 该采集器的含氧量， 以使该含有乳酸菌的样本的质量能够维持一定水平， 以利于 后续步骤 (b)能够筛选到更多的乳酸菌菌种。 在本发明的较佳实施例中， 该采集器 于开封前为无菌状态， 以避免该含有乳酸菌的样本受到污染而影响筛菌结果， 且 该采集器为可透视的容器， 并且该氧气指示剂是以颜色变化作为指示该采集器内 部的含氧量， 以使使用者可以由该采集器外部即可得知该采集器内部含氧量。 在 实施例中， 低含氧量时该氧气指示剂呈粉红色， 高含氧量时该氧气指示剂则呈紫 色。 In addition, since the lactic acid bacteria are mostly anaerobic bacteria, in order to increase the survival rate of the lactic acid bacteria in the sample containing the lactic acid bacteria, and further, the more and more complete lactic acid bacteria species can be obtained by the screening step of the step (b), The sample collector of the sample containing the lactic acid bacteria is a sample collector capable of reducing the oxygen content, and during the collection process, the sample containing the lactic acid bacteria is preferably placed at room temperature for not more than 30 minutes for the fresh lactic acid bacteria-containing sample, especially Fetuses containing lactic acid bacteria are better than one year of birth, because the intestines are micro The species species will decrease with age; the sample containing the lactic acid bacteria is placed in a sealable collector so that the sample containing the lactic acid bacteria can be isolated from the outside, and the deoxidizer and the oxygen indicator are built in the collector to The inside of the collector is in a low oxygen state, and in order to prevent the collector from being imperceptibly damaged during the screening process, the interior is in a high oxygen state (which is an oxygen content in the general atmosphere), or a deoxidizer. When the reaction has been completed and the deoxidation cannot be continued, the collector is in a high oxygen state, but since the amount of oxygen is not determined by the naked eye, the oxygen indicator can be used to make the user of the collector easy. The oxygen content of the collector is judged so that the quality of the sample containing the lactic acid bacteria can be maintained at a certain level, so that the subsequent step (b) can select more lactic acid bacteria species. In a preferred embodiment of the invention, the collector is sterile prior to opening to avoid contamination of the sample containing the lactic acid bacteria to affect the screening result, and the collector is a see-through container, and the oxygen indication The agent uses the color change as an indication of the oxygen content inside the collector, so that the user can know the oxygen content inside the collector from the outside of the collector. In the embodiment, the oxygen indicator is pink when the oxygen content is low, and the oxygen indicator is purple when the oxygen content is high.
由于本发明的步骤 (b)的筛菌步骤为一般微生物筛菌的步骤， 因此不再多加详 述， 但是由于要筛选培养纯化的是来自人体的乳酸菌， 因此培养的条件为无氧环 境且温度 37(±5%)度， 而培养时间约为 20(±5%)小时； 由于不同的乳酸菌菌种所 需要生长环境不完全相同， 因此在本发明中所选用的培养基不只一种， 以期培养 出更多种的乳酸菌菌种。 在本发明中， 选用针对乳酸菌的选择性培养基为 MRS、 M17及 MRS+0.5%半胱氨酸， 由于 MRS、 M17及 MRS+0.5%半胱氨酸的配方 为本领域技术人员能够取得， 因此不再多加赘述。 确认固态培养基的菌落 (colony) 为单一菌落后， 再将不同菌落分别培养于液态培养基中， 再通过 HPLC分析， 及 革兰氏染色 (gram staining), 及显微镜检验照相， 以初步判定是否为乳酸菌， 例如 乳酸菌为革兰氏阳性， 且再依 HPLC分析及显微镜检验照相的结果， 对所筛选及 纯化培养的乳酸菌进行初步分类及甘油保存， 例如分类可依据显微镜检验照相中 各个乳酸菌的形状不同而分类， 例如杆状或螺旋状或双叉杆状等。 Since the screening step of the step (b) of the present invention is a general microbial screening step, it will not be described in detail, but since the lactic acid bacteria from the human body are purified by screening and culture, the culture conditions are an oxygen-free environment and the temperature. 37 (±5%) degrees, and the culture time is about 20 (±5%) hours; since the growth environments required by different lactic acid bacteria species are not completely the same, there is more than one medium selected in the present invention, in view of More varieties of lactic acid bacteria are cultivated. In the present invention, the selective medium for lactic acid bacteria is MRS, M17 and MRS+0.5% cysteine, and the formulas of MRS, M17 and MRS+0.5% cysteine can be obtained by those skilled in the art. Therefore, no more details will be given. Confirm that the colonies of the solid medium are backwards of a single strain, and then different colonies are separately cultured in a liquid medium, and then analyzed by HPLC, gram staining, and microscopic examination to determine whether or not For lactic acid bacteria, such as lactic acid bacteria, Gram-positive, and according to the results of HPLC analysis and microscopic examination, preliminary screening and glycerol preservation of the selected and purified lactic acid bacteria, for example, classification according to the shape of each lactic acid bacteria in the microscope Differently classified, such as rod or spiral or double fork.
之后， 在步骤 (c)中， 将筛选及纯化培养的乳酸菌进行乳酸菌菌种鉴定及生理 试验， 生理测试的项目是选自革兰氏染色、 抗生素耐受性、 抗菌活性、 耐酸试验、 耐胆盐试验、 耐盐试验组合中的一种或两种以上的组合。 由于菌种鉴定为一般微 生物鉴定的步骤， 因此不再多加详述， 但在本发明的较佳实施例中， 其中菌种鉴 定是由政府认可单位进行鉴定而得到一第一菌种鉴定结果， 而非执行步骤 (a)及步
骤 (b)及步骤 (c)的生理测试及步骤 (d)和步骤 (e)的单位，以使该个体可将取得的该乳 酸菌产品， 再经由同一或另一政府认可单位进行鉴定而得到一第二菌种鉴定结果， 以使该个体可供通过比对该第一及第二菌种鉴定结果， 而使该个体可以确认该乳 酸菌产品是来自该个体所筛选纯化培养的乳酸菌菌种。 Then, in step (c), the lactic acid bacteria cultured and purified by the screening and purification are subjected to lactic acid bacteria species identification and physiological tests, and the physiological test items are selected from the group consisting of Gram staining, antibiotic resistance, antibacterial activity, acid resistance test, and gall bladder resistance. One or a combination of two or more of a salt test and a salt tolerance test combination. Since the strain identification is a step of general microbial identification, it will not be described in detail, but in the preferred embodiment of the present invention, the identification of the strain is determined by a government-approved unit to obtain a first strain identification result. Instead of performing steps (a) and steps The physiological test of step (b) and step (c) and the unit of step (d) and step (e), so that the individual can obtain the obtained lactic acid bacteria product and identify it by the same or another government-approved unit. A second strain is identified to enable the individual to pass the identification of the first and second strains, so that the individual can confirm that the lactic acid bacteria product is a lactic acid bacteria species selected from the individual for screening and purification.
而关于生理试验中的抗生素耐受性是通过含有抗生素的贴片贴于长满微生物 的固态培养基上， 观察因该抗生素而对微生物的抑制环圈大小， 抑制环圈越大表 示该微生物对于该抗生素的耐受性越小。 在本发明的抗生素耐受性试验中， 选用 四种常见抗生素及各抗生素贴片浓度： 氯霉素 (chloramphenicol )(30 g)， 青霉素 (penicillin) (10 g), 链霉素 (streptomycin) (10 g), 四环素 (tetracycline) (30 g)。 关于抗菌活性， 与抗生素的耐受性试验相似， 也是观察抑制环圈大小， 抑制环圈 越大表示该微生物对于该另一微生物的抗菌能力越大， 但将抗生素改成另一微生 物。 在本发明的抗菌活性试验中， 所选用的另一微生物包括下列三种常见之微生 物： 大肠杆菌（Escfier/'cfv'a co/i); 金黄色葡萄球菌（Step/^/ococo/s aureus); 鼠伤 寒沙门氏菌 (Sa/mone//s typhimurium)。 而关于耐酸试验， 是将乳酸菌培养于酸性 环境， 在本发明的耐酸试验中， 所选用酸性环境的实验组及对照组分别为 pH 2.0; pH 7.0, 并记录该乳酸菌的菌数 (CFU/g)(CFU : colony forming unit)。 而关于耐胆 盐试验， 是将乳酸菌培养于含有胆盐的环境， 在本发明的耐胆盐试验中， 选用牛 的胆盐，其中对照组及各个胆盐浓度及其酸碱值分别为 0% 胆盐 （pH 3.98)， 0.3 % 胆盐 (pH 5.08)及 0.5 %胆盐 (pH 5.78) ， 并记录该乳酸菌的菌数。 关于耐盐试验， 是将乳酸菌培养于含有盐 (NaCI)的环境，其中对照组及各个盐浓度及其酸碱值分别 为 0% NaCI (pH 3.98)， 5 % NaCI (pH 4.13)及 10 % NaCI (pH 5.52) ， 并记录该 乳酸菌的菌数。 The antibiotic resistance in the physiological test is carried out by attaching a patch containing an antibiotic to a solid medium filled with microorganisms, and observing the size of the inhibition loop of the microorganism by the antibiotic, and the larger the inhibition loop indicates that the microorganism is The tolerance of this antibiotic is smaller. In the antibiotic tolerance test of the present invention, four common antibiotics and each antibiotic patch concentration are selected: chloramphenicol (30 g), penicillin (10 g), streptomycin (streptomycin) ( 10 g), tetracycline (30 g). Regarding the antibacterial activity, similar to the antibiotic resistance test, the size of the inhibition loop was also observed. The larger the inhibition loop, the greater the antimicrobial ability of the microorganism for the other microorganism, but the change of the antibiotic to another microorganism. In the antibacterial activity test of the present invention, another microorganism selected includes the following three common microorganisms: Escherichia coli (Escfier/'cfv'a co/i); Staphylococcus aureus (Step/^/ococo/s aureus) ); Salmonella typhimurium (Sa/mone//s typhimurium). In the acid resistance test, the lactic acid bacteria were cultured in an acidic environment. In the acid resistance test of the present invention, the experimental group and the control group selected for the acidic environment were pH 2.0; pH 7.0, and the number of bacteria of the lactic acid bacteria (CFU/g) was recorded. (CFU: colony forming unit). In the bile salt test, the lactic acid bacteria are cultured in an environment containing bile salts. In the bile salt test of the present invention, bovine bile salts are used, wherein the concentration of the control group and each bile salt and its pH value are respectively 0. % bile salt (pH 3.98), 0.3% bile salt (pH 5.08) and 0.5% bile salt (pH 5.78), and the number of bacteria of the lactic acid bacteria was recorded. For the salt tolerance test, the lactic acid bacteria were cultured in an environment containing salt (NaCI), wherein the control group and each salt concentration and its pH value were 0% NaCI (pH 3.98), 5% NaCI (pH 4.13) and 10%, respectively. NaCI (pH 5.52), and record the number of bacteria in the lactic acid bacteria.
在步骤 (d)中， 依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌 种鉴定结果，用以比对安全可靠 (Generally Regarded as Safe, GRAS)等级的 FDA 认可安全表列， 从而判断从该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种是 否为安全可靠等级的乳酸菌菌种， 以确保该个体食用该乳酸菌菌种的安全性。 In the step (d), the lactic acid bacteria-containing sample is screened and purified according to the sample containing the lactic acid bacteria in the step (c) for comparison with the FDA-approved safety list of the Generally Regarded as Safe (GRAS) grade. Therefore, it is judged whether the cultured lactic acid bacteria species are selected from the lactic acid bacteria-containing sample to be safe and reliable, and the lactic acid bacteria species are safe and reliable to ensure the safety of the lactic acid bacteria species.
在步骤 (e)中， 再依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌 菌种生理测试结果， 及将步骤 (d)中该安全可靠等级乳酸菌菌种， 制成乳酸菌产品。 在本发明的实施例中， 先将安全可靠等级之乳酸菌菌种冷冻干燥形成一菌粉， 再 以该菌粉制成乳酸菌产品， 其中该乳酸菌产品包含粉包、 饮品、 果冻、 优格、 乳
酸菌颗粒或胶囊等， 以使该个体可以通过食用自体或其亲属来源的乳酸菌所制成 的乳酸菌产品， 以达到补充自体乳酸菌的目的。 由于将活菌冷冻干燥成菌粉及将 乳酸菌制成乳酸菌产品 (如优格、 酸奶、 乳酸菌颗粒、 乳酸菌胶囊、 乳酸菌饮料等) 的技术为本领域技术人员所知悉， 因此不再多加赘述。 In the step (e), the physiological test result of the cultured lactic acid bacteria strain is screened and purified according to the sample containing the lactic acid bacteria in the step (c), and the safe and reliable grade lactic acid bacteria strain in the step (d) is made into the lactic acid bacteria product. . In the embodiment of the present invention, the lactic acid bacteria strain of the safe and reliable grade is freeze-dried to form a bacterial powder, and the lactic acid bacteria product is further prepared by using the bacterial powder, wherein the lactic acid bacteria product comprises a powder package, a drink, a jelly, a yogurt, a milk Acid bacteria particles or capsules, etc., so that the individual can obtain the lactic acid bacteria product prepared by lactic acid bacteria derived from the body or its relatives to achieve the purpose of supplementing the autologous lactic acid bacteria. Since the technique of freeze-drying living bacteria into bacterial powder and lactic acid bacteria into lactic acid bacteria products (e.g., yogurt, yoghurt, lactic acid bacteria granules, lactic acid bacteria capsules, lactic acid bacteria beverages, etc.) is known to those skilled in the art, no further description will be given.
由于乳酸菌除了肠胃道的保健功能之外， 更有许多其它方面的应用， 因此乳 酸菌相关的研究及产品开发也受到相当的重视， 且不同的乳酸菌菌种对人体的效 益也略有不同， 因此每一乳酸菌菌种的实验结果都是分别独立的， 而且由相近的 菌种所推估的信息是无法被采信的。 因此， 在本发明的实施例中， 更可将步骤 (C) 中纯化培养的乳酸菌的菌种鉴定及生理测试结果建立一该个体的乳酸菌菌种数 据， 且还将该个体的乳酸菌菌种数据更建立于一乳酸菌菌种数据库中， 该乳酸菌 菌种数据库可供记录许多个体的乳酸菌菌种资料； 而由每个个体的乳酸菌菌种数 据所组成的乳酸菌菌种数据库， 可以由该乳酸菌菌种数据库中确切提供纪录的每 个乳酸菌菌种数据， 而非由相近的乳酸菌菌种所推估的资料。 此外， 该乳酸菌菌 种数据库另可与一该个体和其亲属的生物医学数据库结合， 用以分析该个体体内 的乳酸菌菌相与该个体和其亲属的生物医学数据的关联性。 而且， 该乳酸菌菌种 数据库与该个体和其亲属的生物医学数据库可供日后作学术研究或产品开发之 用， 以节省日后的研究人力资源， 且可提供学术研究或产品开发人员从该乳酸菌 菌种数据库与该个体和其亲属的生物医学数据库中， 选择其所想要的乳酸菌菌种 与该个体和其亲属的生物医学资料。 In addition to the health functions of the gastrointestinal tract, lactic acid bacteria have many other applications. Therefore, research and product development related to lactic acid bacteria have received considerable attention, and different lactic acid bacteria strains have slightly different benefits to the human body. The experimental results of a lactic acid bacteria strain are independent, and the information estimated by similar strains cannot be accepted. Therefore, in the embodiment of the present invention, the strain identification and physiological test results of the purified lactic acid bacteria in the step (C) can be used to establish the lactic acid bacteria species data of the individual, and the lactic acid bacteria species data of the individual is also It is further established in a lactic acid bacteria strain database, which can record the lactic acid bacteria species data of many individuals; and the lactic acid bacteria strain database composed of the lactic acid bacteria species data of each individual can be composed of the lactic acid bacteria strain The database provides exactly the data for each lactic acid bacteria record, not the data estimated by similar lactic acid bacteria. In addition, the lactic acid bacteria database can be combined with a biomedical database of the individual and its relatives to analyze the association of the lactic acid bacteria phase in the individual with the biomedical data of the individual and their relatives. Moreover, the lactic acid bacteria database and the biomedical database of the individual and their relatives can be used for academic research or product development in the future to save future research human resources, and can provide academic research or product developers from the lactic acid bacteria The database and the biomedical database of the individual and its relatives select the biomedical data of the desired lactic acid bacteria species and the individual and their relatives.
图 2为本发明生产自体乳酸菌的系统 100的方块示意图， 主要包含： 一乳酸 菌储存装置 101，用于储存从一个体的含有乳酸菌的样本所搜集的乳酸菌；一分析 乳酸菌装置 102，用于分析并储存从该个体的含有乳酸菌的样本所搜集的该乳酸菌 的资料， 而该乳酸菌的数据是选自由革兰氏染色、 耐酸测试、 耐胆盐测试、 耐盐 性分析、 抗生素耐受性分析与抗菌活性分析所组成的群组； 与一乳酸菌生产装置 103， 其连接至该乳酸菌储存装置 101与该分析乳酸菌装置 102， 用于将该分析乳 酸菌装置 102所分析适合该个体的乳酸菌从该乳酸菌储存装置 101取出并制成一 乳酸菌产品， 此产品可依该个体的喜好制成粉包、 饮品、 果冻、 优格、 乳酸菌颗 粒或胶囊。 2 is a block diagram of a system 100 for producing autologous lactic acid bacteria according to the present invention, which mainly comprises: a lactic acid bacteria storage device 101 for storing lactic acid bacteria collected from a sample containing lactic acid bacteria; and an analytical lactic acid bacteria device 102 for analyzing and Storing data of the lactic acid bacteria collected from the individual's lactic acid bacteria-containing sample, and the lactic acid bacteria data is selected from the group consisting of Gram staining, acid resistance test, bile salt test, salt tolerance analysis, antibiotic resistance analysis and antibacterial a group consisting of activity analysis; and a lactic acid bacteria production device 103 connected to the lactic acid bacteria storage device 101 and the analytical lactic acid bacteria device 102 for analysing the lactic acid bacteria suitable for the individual from the analytical lactic acid bacteria device 102 from the lactic acid bacteria storage device 101 is taken out and made into a lactic acid bacteria product, which can be made into a powder package, a drink, a jelly, a yogurt, a lactic acid bacteria granule or a capsule according to the individual's preference.
本发明的生产自体乳酸菌的系统 100设置于一乳酸菌生产公司， 另包含一管 理装置 104， 其连接至该乳酸菌生产装置 103， 其中该管理装置 104储存有该个
体所签署的合约， 并依照该合约管理该乳酸菌生产装置 103。 The system 100 for producing autologous lactic acid bacteria of the present invention is provided in a lactic acid bacteria production company, and further comprises a management device 104 connected to the lactic acid bacteria production device 103, wherein the management device 104 stores the one The contract signed by the body, and the lactic acid bacteria producing device 103 is managed in accordance with the contract.
依据本发明的生产自体乳酸菌的系统， 在较佳实施例中， 该合约约定该个体 同意该乳酸菌生产公司无偿使用该乳酸菌于该乳酸菌生产公司自制产品； 在另一 较佳实施例中， 该合约约定该个体同意该乳酸菌生产公司将该乳酸菌转卖第三方 且该乳酸菌生产公司须提成该乳酸菌售价的一定比例予该个体。 According to the system for producing an autologous lactic acid bacteria according to the present invention, in a preferred embodiment, the contract stipulates that the individual agrees that the lactic acid bacteria producing company uses the lactic acid bacteria for the self-made product of the lactic acid bacteria producing company; in another preferred embodiment, the contract It is agreed that the individual agrees that the lactic acid bacteria production company resells the lactic acid bacteria to a third party and that the lactic acid bacteria production company must present a certain percentage of the lactic acid bacteria price to the individual.
综上所述， 本发明确实符合产业利用性， 且未于申请前见于刊物或公开使用， 亦未为公众所知悉， 且具有非显而易见性， 符合可专利的要件， 因此依法提出专 利申请。 In summary, the present invention is indeed in line with industrial applicability, and is not found in publications or publicly used before application, nor is it known to the public, and is non-obvious and conforms to patentable requirements. Therefore, a patent application is filed according to law.
以上所述仅为本发明在产业上的一较佳实施例， 凡依本发明申请专利范围所 作的等同变化， 皆属于本发明权利要求的范围。
The above is only a preferred embodiment of the present invention in the industry, and all equivalent changes made by the scope of the invention are within the scope of the claims of the present invention.
Claims
1 . 一种自体来源乳酸菌的制造方法， 包括下列步骤： What is claimed is: 1. A method of producing an lactic acid bacterium of autologous origin, comprising the steps of:
(a μ人一个体采集该个体的含有乳酸菌的样本； (a μ person collects a sample of the individual containing lactic acid bacteria;
(b) 从该个体的含有乳酸菌的样本中筛选乳酸菌菌种，并将筛选出的乳酸菌菌 种进行纯化培养； (b) screening the lactic acid bacteria species from the individual lactic acid bacteria-containing sample, and purifying and cultivating the selected lactic acid bacteria species;
(c) 对从该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种分别进行菌种鉴 定及生理测试； (c) performing strain identification and physiological testing on the lactic acid bacteria strains selected from the lactic acid bacteria-containing samples for screening and purification;
(d) 依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种鉴定结 果， 用以比对安全可靠 (Generally Regarded as Safe, GRAS)等级的 FDA认可安 全表列， 从而判断从该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种是否为安 全可靠等级的乳酸菌菌种； 以及 (d) Screening and purifying the cultured lactic acid bacteria strains according to the lactic acid bacteria-containing sample in step (c), in order to compare the FDA-approved safety list of the General Regarded as Safe (GRAS) grade, thereby judging The lactic acid bacteria-containing sample is used to screen and purify whether the cultured lactic acid bacteria species are safe and reliable grades of lactic acid bacteria;
(e) 另依据步骤 (c)中该含有乳酸菌的样本筛选并纯化培养的乳酸菌菌种生理 测试结果， 以决定将步骤 (d)中该安全可靠等级乳酸菌菌种制成乳酸菌产品。 (e) Further screening and purifying the physiological test results of the cultured lactic acid bacteria according to the sample containing the lactic acid bacteria in the step (c), to determine that the safe and reliable grade of the lactic acid bacteria in the step (d) is made into a lactic acid bacteria product.
2. 根据权利要求 1所述的自体来源乳酸菌的制造方法， 其中该生理测试是选 自革兰氏染色、 抗生素耐受性、 抗菌活性、 耐酸试验、 耐胆盐试验、 耐盐试验中 的一种或两种以上的组合。 The method for producing an autologously derived lactic acid bacterium according to claim 1, wherein the physiological test is one selected from the group consisting of Gram staining, antibiotic resistance, antibacterial activity, acid resistance test, bile salt resistance test, and salt tolerance test. Kind or a combination of two or more.
3. 根据权利要求 1所述的自体来源乳酸菌的制造方法， 其中， 采集该个体的 含有乳酸菌的样本的采集器是一可降低含氧量的样本采集器。 The method for producing an autologously derived lactic acid bacterium according to claim 1, wherein the collector for collecting the lactic acid bacteria-containing sample of the individual is a sample collector capable of reducing oxygen content.
4. 根据权利要求 1所述的自体来源乳酸菌的制造方法， 其中将安全可靠等级 的乳酸菌菌种冷冻干燥形成一菌粉， 再以该菌粉制成乳酸菌产品供该个体或其亲 属使用。 The method for producing a self-derived lactic acid bacterium according to claim 1, wherein a lactic acid bacteria strain of a safe and reliable grade is freeze-dried to form a bacterium powder, and the lactic acid bacteria product is produced from the bacterium powder for use by the individual or a relative thereof.
5. 根据权利要求 4所述的自体来源乳酸菌的制造方法， 其中该乳酸菌产品包 含粉包、 饮品、 果冻、 优格、 乳酸菌颗粒或胶囊。 The method for producing an autologously derived lactic acid bacterium according to claim 4, wherein the lactic acid bacteria product comprises a powder packet, a drink, a jelly, a yogurt, a lactic acid bacteria granule or a capsule.
6. —种生产自体乳酸菌的系统， 其包含- 一乳酸菌储存装置， 用于储存从一个体的含有乳酸菌的样本所搜集的乳酸菌；
一分析乳酸菌装置， 用于分析并储存从该个体的含有乳酸菌的样本所搜集的 该乳酸菌的资料； 以及 6. A system for producing an autologous lactic acid bacteria, comprising: a lactic acid bacteria storage device for storing lactic acid bacteria collected from a sample containing lactic acid bacteria; An analytical lactic acid bacteria apparatus for analyzing and storing data of the lactic acid bacteria collected from the individual's lactic acid bacteria-containing sample;
一乳酸菌生产装置， 其连接至该乳酸菌储存装置与该分析乳酸菌装置， 用于 将该分析乳酸菌装置所分析适合该个体的乳酸菌从该乳酸菌储存装置取出并制成 一乳酸菌产品。 A lactic acid bacteria producing apparatus connected to the lactic acid bacteria storage device and the analytical lactic acid bacteria device for taking out lactic acid bacteria suitable for the individual analyzed by the analytical lactic acid bacteria device from the lactic acid bacteria storage device and forming a lactic acid bacteria product.
7. 根据权利要求 6所述的生产自体乳酸菌的系统， 其中该乳酸菌的数据是选 自由革兰氏染色、 耐酸测试、 耐胆盐测试、 耐盐性分析、 抗生素耐受性分析与抗 菌活性分析所组成的群组。 7. The system for producing autologous lactic acid bacteria according to claim 6, wherein the data of the lactic acid bacteria is selected from the group consisting of Gram staining, acid resistance test, bile salt resistance test, salt tolerance analysis, antibiotic resistance analysis and antibacterial activity analysis. The group formed.
8. 根据权利要求 6所述的生产自体乳酸菌的系统， 其中该乳酸菌产品包含粉 包、 饮品、 果冻、 优格、 乳酸菌颗粒或胶囊。 8. The system for producing an autologous lactic acid bacterium according to claim 6, wherein the lactic acid bacteria product comprises a powder packet, a drink, a jelly, a yogurt, a lactic acid bacteria granule or a capsule.
9. 根据权利要求 6所述的生产自体乳酸菌的系统， 其另包含一管理装置， 该 管理装置连接至该乳酸菌生产装置， 其中该管理装置储存有该个体所签署的合约， 并依照该合约管理该乳酸菌生产装置。 9. The system for producing an autologous lactic acid bacterium according to claim 6, further comprising a management device connected to the lactic acid bacteria production device, wherein the management device stores a contract signed by the individual and is managed according to the contract The lactic acid bacteria production device.
10. 根据权利要求 9 所述的生产自体乳酸菌的系统， 其设置于一乳酸菌生产 公司。 10. The system for producing an autologous lactic acid bacterium according to claim 9, which is provided in a lactic acid bacteria production company.
11 . 根据权利要求 10所述的生产自体乳酸菌的系统， 其中该合约约定该个体 同意该乳酸菌生产公司无偿使用该乳酸菌于该乳酸菌生产公司自制产品。 The system for producing an autologous lactic acid bacterium according to claim 10, wherein the contract stipulates that the individual agrees that the lactic acid bacteria producing company uses the lactic acid bacteria for the self-made product of the lactic acid bacteria producing company.
12. 根据权利要求 10所述的生产自体乳酸菌的系统， 其中该合约约定该个体 同意该乳酸菌生产公司将该乳酸菌转卖第三方且该乳酸菌生产公司须提成该乳酸 菌售价的一定比例予该个体。
12. The system for producing an autologous lactic acid bacterium according to claim 10, wherein the contract stipulates that the individual agrees that the lactic acid bacteria producing company resells the lactic acid bacteria to a third party and the lactic acid bacteria producing company must present a proportion of the lactic acid bacteria to the individual.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/082208 WO2016008084A1 (en) | 2014-07-15 | 2014-07-15 | Autologous lactic acid bacteria manufacturing method and system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/082208 WO2016008084A1 (en) | 2014-07-15 | 2014-07-15 | Autologous lactic acid bacteria manufacturing method and system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016008084A1 true WO2016008084A1 (en) | 2016-01-21 |
Family
ID=55077795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2014/082208 WO2016008084A1 (en) | 2014-07-15 | 2014-07-15 | Autologous lactic acid bacteria manufacturing method and system |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016008084A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113923993A (en) * | 2019-05-15 | 2022-01-11 | 米罗拉夫·拉巴斯 | A method for producing milk and dairy supplements with unique fatty acid composition by restoring symbiotic natural microbial community |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179020A (en) * | 1991-08-19 | 1993-01-12 | Bio Techniques Laboratories, Inc. | Antibiotic resistant strain of lactobacillus acidophilus |
| WO2003010299A1 (en) * | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | Probiotic lactobacillus casei strains |
| CN101307354A (en) * | 2008-07-07 | 2008-11-19 | 中国科学院微生物研究所 | Method for screening strains with high lactic acid yield |
| CN103333847A (en) * | 2013-07-22 | 2013-10-02 | 扬州大学 | Lactobacillus fermenti grx08 with function of assisting blood fat reduction and application of lactobacillus fermenti grx08 |
| CN103710290A (en) * | 2013-12-31 | 2014-04-09 | 广西皇氏甲天下乳业股份有限公司 | Probiotics lactobacillus rhamnosus hsryfm1301 originated in Guangxi Bama longevity village and application of probiotics lactobacillus rhamnosus hsryfm1301 |
-
2014
- 2014-07-15 WO PCT/CN2014/082208 patent/WO2016008084A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179020A (en) * | 1991-08-19 | 1993-01-12 | Bio Techniques Laboratories, Inc. | Antibiotic resistant strain of lactobacillus acidophilus |
| WO2003010299A1 (en) * | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | Probiotic lactobacillus casei strains |
| CN101307354A (en) * | 2008-07-07 | 2008-11-19 | 中国科学院微生物研究所 | Method for screening strains with high lactic acid yield |
| CN103333847A (en) * | 2013-07-22 | 2013-10-02 | 扬州大学 | Lactobacillus fermenti grx08 with function of assisting blood fat reduction and application of lactobacillus fermenti grx08 |
| CN103710290A (en) * | 2013-12-31 | 2014-04-09 | 广西皇氏甲天下乳业股份有限公司 | Probiotics lactobacillus rhamnosus hsryfm1301 originated in Guangxi Bama longevity village and application of probiotics lactobacillus rhamnosus hsryfm1301 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113923993A (en) * | 2019-05-15 | 2022-01-11 | 米罗拉夫·拉巴斯 | A method for producing milk and dairy supplements with unique fatty acid composition by restoring symbiotic natural microbial community |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vasiee et al. | Isolation, identification and characterization of probiotic Lactobacilli spp. from Tarkhineh. | |
| Damaceno et al. | Evaluation of potential probiotics isolated from human milk and colostrum | |
| Botta et al. | In vitro selection and characterization of new probiotic candidates from table olive microbiota | |
| Saarela et al. | Stationary‐phase acid and heat treatments for improvement of the viability of probiotic lactobacilli and bifidobacteria | |
| CN113088463B (en) | Lactobacillus acidophilus with probiotic characteristics and application thereof | |
| CN104928208B (en) | Lactobacillus plantarum Lp90, and screening method and application thereof | |
| Díaz-Vergara et al. | Encapsulated whey–native yeast Kluyveromyces marxianus as a feed additive for animal production | |
| CN110577912B (en) | Lactobacillus gasseri and application thereof in preparing fermented milk | |
| CN110452828B (en) | Lactobacillus reuteri strain and application thereof | |
| CN111778180B (en) | Breast milk source lactobacillus plantarum and application thereof | |
| Denkova et al. | Antimicrobial activity of probiotic lactobacilli, bifidobacteria and propionic acid bacteria, isolated from different sources | |
| Dahiya et al. | Evaluation of survival, free radical scavenging and human enterocyte adherence potential of lactobacilli with anti‐obesity and anti‐inflammatory CLA isomer‐producing attributes | |
| Lee et al. | Safety and risk assessment of the genetically modified Lactococci on rats intestinal bacterial flora | |
| Antonio et al. | Bifidobacteria as potential functional starter cultures: a case study by MSc students in Food Science and Technology (University of Foggia, Southern Italy) | |
| Singh et al. | Evaluation of Market Curd for Sanitary Quality and Bacteriocin-Producing Lactic acid Bacteria for Potential Application as a Natural, Healthy Food Preservative | |
| WO2016008084A1 (en) | Autologous lactic acid bacteria manufacturing method and system | |
| JP7358002B2 (en) | Bacillus bacteria, interleukin-22 production inducer, skin barrier function enhancer | |
| JP2022549015A (en) | Lactobacillus plantarum derived from breast milk and uses thereof | |
| Dehghani Champiri et al. | Isolation and identification of Lactobacillus brevis from cottage cheese of Bazoft City, Iran and evaluation of its antimicrobial activity against some pathogenic microorganisms | |
| Chu‐Ky et al. | Acid adaptation to improve viability and X‐prolyl dipeptidyl aminopeptidase activity of the probiotic bacterium Lactobacillus fermentum HA 6 exposed to simulated gastrointestinal tract conditions | |
| Aktaş et al. | Probiotic and technological properties of isolates from homemade and industrial yoghurts | |
| CN112708577B (en) | Lactobacillus fermentum DALI02 with high intestinal adhesion and immunoregulation function and application thereof | |
| Champiri et al. | Isolation and Identification of Lactobacillus brevis from Local Cheese of Bazoft and Evaluation of Antimicrobial Activity Against Some Pathogenic Microorganisms. | |
| Shaikh et al. | Isolation and enumeration of probiotic microorganisms from fermented idli batter | |
| CN110396487B (en) | Lactobacillus acidophilus capable of improving intestinal flora and regulating immunity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14897495 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14897495 Country of ref document: EP Kind code of ref document: A1 |